[Form 4] Synopsys Inc Insider Trading Activity
Shelagh Glaser, Chief Financial Officer of Synopsys, filed a Form 4 reporting option exercises and share transactions executed pursuant to a Rule 10b5-1 trading plan. The report shows transactions dated 09/05/2025 under a 10b5-1 plan adopted January 13, 2025. On that date Ms. Glaser acquired 2,612 shares via a $348.17-priced non-qualified option and 1,043 shares via a $354.45-priced non-qualified option. The Form also reports corresponding dispositions of 2,612 and 1,043 shares at $609.77. Beneficial ownership totals shown after the transactions include 17,929, 16,360 and 15,317 shares in various lines. The Form 4 was submitted by POA Liz Ramirez on 09/09/2025.
- Transactions executed under a Rule 10b5-1 plan (adopted January 13, 2025) which provides an affirmative defense for pre-established trades
 - Documented option exercises and corresponding share trades with explicit exercise prices ($348.17 and $354.45) and sale price ($609.77) reported
 
- None.
 
Insights
TL;DR: CFO executed option exercises and share sales under a pre-established 10b5-1 plan on 09/05/2025.
The filing documents simultaneous option exercises and share dispositions for Shelagh Glaser executed pursuant to a Rule 10b5-1 plan adopted January 13, 2025. The exercises relate to non-qualified stock options with strike prices of $348.17 and $354.45 producing 2,612 and 1,043 underlying shares respectively. The reported sales prices are $609.77 per share for each disposed tranche. These are routine insider liquidity events documented under an affirmative defense trading plan and do not include additional commentary on use of proceeds or changes to compensation terms.
TL;DR: Transactions were conducted under a documented 10b5-1 plan, providing procedural compliance but no new governance actions.
The Form 4 indicates that the CFO's trades were effected pursuant to a 10b5-1 trading plan adopted earlier in 2025 and the filing was executed by a power of attorney. From a governance perspective, the filing shows compliance with insider-trading protocols; it does not disclose any management departures, new equity grants beyond the listed exercises, or governance changes. All material details in the filing are transaction-level disclosures consistent with Section 16 reporting requirements.